Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regenxbio Inc (NQ: RGNX )

20.34 +0.24 (+1.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 251,096
Open 20.17
Bid (Size) 18.91 (1)
Ask (Size) 21.00 (40)
Prev. Close 20.10
Today's Range 19.56 - 20.52
52wk Range 17.02 - 35.73
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for Regenxbio
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
 
Via Benzinga

Performance

YTD
-8.58%
-8.58%
1 Month
+10.24%
+10.24%
3 Month
-13.23%
-13.23%
6 Month
-9.68%
-9.68%
1 Year
-7.67%
-7.67%

More News

Read More
Regenxbio's Return On Capital Employed Insights
Via Benzinga
Analyst Expectations for Regenxbio's Future
Via Benzinga
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?
Via The Motley Fool
Tesla To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
Earnings Preview: Regenxbio
Via Benzinga
Looking Into Regenxbio's Return On Capital Employed
Via Benzinga
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
5 Analysts Have This to Say About Regenxbio
Via Benzinga
What 5 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
Earnings Scheduled For February 28, 2023
Via Benzinga
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity
Via Benzinga
Recap: Regenxbio Q3 Earnings
Via Benzinga
Despite Solid Efficacy From Gene Therapy, This Analyst Cuts REGENXBIO's Price Target
Via Benzinga
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Via FinancialNewsMedia
Exposures COVID-19
Regenxbio's Earnings Outlook
Via Benzinga
Alphabet To $114? Plus This Analyst Predicts $145 For Disney
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
4 Analysts Have This to Say About Regenxbio
Via Benzinga
Earnings Scheduled For November 3, 2022
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Regenxbio's Earnings Outlook
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.